Effects of levcromakalim in patients with migraine aura without headache: An experimental study.

IF 5 2区医学 Q1 CLINICAL NEUROLOGY

Cephalalgia Pub Date : 2024-08-01 DOI:10.1177/03331024241274366

Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski, Messoud Ashina

{"title":"Effects of levcromakalim in patients with migraine aura without headache: An experimental study.","authors":"Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski, Messoud Ashina","doi":"10.1177/03331024241274366","DOIUrl":null,"url":null,"abstract":"Background/hypothesis: Levcromakalim has previously been shown to induce attacks of migraine with aura in certain individuals. In this study, we tested the migraine-inducing effect of levcromakalim in a cohort of participants with migraine aura without headache.Methods: In a double-blind, randomized, placebo-controlled cross-over study, eight adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 h following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-h observation period.Results: Five participants (62.5%) developed migraine of any type following levcromakalim compared with three participants (37.5%) following placebo. No participants developed aura following levcromakalim.Conclusion/interpretation: Our findings suggest that the aura-inducing effect of levcromakalim is likely not based on direct induction of cortical spreading depression but may involve activation of the trigeminovascular system. This hypothesis should be further explored in future studies.Clinicaltrials.gov identifier: NCT04905654.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241274366"},"PeriodicalIF":5.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024241274366","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/hypothesis: Levcromakalim has previously been shown to induce attacks of migraine with aura in certain individuals. In this study, we tested the migraine-inducing effect of levcromakalim in a cohort of participants with migraine aura without headache.

Methods: In a double-blind, randomized, placebo-controlled cross-over study, eight adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 h following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-h observation period.

Results: Five participants (62.5%) developed migraine of any type following levcromakalim compared with three participants (37.5%) following placebo. No participants developed aura following levcromakalim.

Conclusion/interpretation: Our findings suggest that the aura-inducing effect of levcromakalim is likely not based on direct induction of cortical spreading depression but may involve activation of the trigeminovascular system. This hypothesis should be further explored in future studies.

Clinicaltrials.gov identifier: NCT04905654.

查看原文本刊更多论文

Levcromakalim 对无头痛先兆偏头痛患者的影响：一项实验研究。

背景/假设：以前曾有研究表明，左旋克罗米林可诱发某些人发作有先兆的偏头痛。在这项研究中，我们在一组有偏头痛先兆但无头痛的参与者中测试了左旋卡林的偏头痛诱发作用：在一项双盲、随机、安慰剂对照的交叉研究中，八名患有先兆偏头痛的成年参与者接受了静脉注射左旋克罗马利姆和生理盐水。研究人员在用药后 24 小时内对头痛、先兆和相关症状进行了评估。主要终点是在24小时观察期内出现有或无先兆的偏头痛样发作：结果：5名参与者（62.5%）在服用左旋卡林后出现任何类型的偏头痛，而服用安慰剂的参与者为3名（37.5%）。没有人在服用左旋卡林后出现先兆：我们的研究结果表明，左旋库马卡林的先兆诱导效应可能不是基于直接诱导皮质扩散抑制，而是可能涉及三叉神经血管系统的激活。这一假设应在今后的研究中进一步探讨：NCT04905654。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia 医学-临床神经学

CiteScore

10.10

自引率

6.10%

发文量

108

审稿时长

4-8 weeks

期刊介绍： Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.